Apomorphine for prolonged disorders of consciousness: a multimodal open-label study.

ABSTRACT:

Background

Apomorphine is a dopaminergic candidate therapy to improve recovery in patients with prolonged disorders of consciousness (PDoC). Behavioural improvements were previously described in non-controlled case series, but its efficacy and neural mechanisms remain largely unknown. This open-label controlled study using multimodal outcome measures investigates the action of apomorphine in severely brain-injured patients.

Methods

Thirteen PDoC patients received 30-day subcutaneous apomorphine treatment (n = 6) or standard care (control group, n = 7) in a neurological rehabilitation centre between February 2018 and January 2021. The apomorphine group was monitored 30 days before treatment initiation, during treatment and one year after treatment. Primary outcome measure was

SUBMITTER: Sanz LRD 

PROVIDER: S-EPMC11609466 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature